During the past decade, TGEN Clinical Research Services at Scottsdale Healthcare conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 3 clinical trials were completed, i.e. on average, 300% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "TGEN Clinical Research Services at Scottsdale Healthcare" #1 sponsor was "Cascadian Therapeutics Inc." with 3 trials, followed by "Alnylam Pharmaceuticals" with 2 trials sponsored, "Novartis Pharmaceuticals" with 2 trials sponsored, "AVEO Pharmaceuticals, Inc." with 1 trials sponsored and "Arno Therapeutics" with 1 trials sponsored. Other sponsors include 10 different institutions and companies that sponsored additional 20 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "TGEN Clinical Research Services at Scottsdale Healthcare" #1 collaborator was "Agensys, Inc." with 1 trials as a collaborator, "American Association for Cancer Research" with 1 trials as a collaborator, "Celgene Corporation" with 1 trials as a collaborator, "National Cancer Institute (NCI)" with 1 trials as a collaborator and "Scottsdale Healthcare" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "TGEN Clinical Research Services at Scottsdale Healthcare" are "Solid Tumors" (6 trials), "Advanced Solid Tumors" (3 trials), "Lymphoma" (3 trials), "Cancer" (2 trials) and "Metastatic Pancreatic Cancer" (2 trials). Many other conditions were trialed in "TGEN Clinical Research Services at Scottsdale Healthcare" in a lesser frequency.

Most popular intervention types in "TGEN Clinical Research Services at Scottsdale Healthcare" are "Drug" (24 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "ALN-VSP02" (2 trials), "Gemcitabine" (2 trials), "PX-12" (2 trials) and "AR-12: (2-Amino-N-[4-[5-(2 phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] phenyl]-acetamide)" (1 trials). Other intervention names were less common.

The vast majority of trials in "TGEN Clinical Research Services at Scottsdale Healthcare" are 24 trials for "All" genders.

Currently, there are NaN active trials in "TGEN Clinical Research Services at Scottsdale Healthcare". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 21 completed trials in TGEN Clinical Research Services at Scottsdale Healthcare, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in TGEN Clinical Research Services at Scottsdale Healthcare, 16 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".